Results from the COAPT trial reported at TCT 2018 and published simultaneously in NEJM

September 23, 2018

SAN DIEGO - September 23, 2018 - Data presented today from the randomized COAPT trial, which have the potential to significantly change current clinical practice, found that patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally tolerated medical therapy demonstrated reduced rates of hospitalizations and death, as well as improved quality-of-life and functional capacity after being treated with the transcatheter MitraClip device.

Findings were reported today at the 30th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. The study was also published simultaneously in the New England Journal of Medicine.

"The prognosis for heart failure patients who develop severe secondary mitral regurgitation is poor with limited treatment options," said Gregg W. Stone, MD, Professor of Medicine at Columbia University Irving Medical Center, and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian/Columbia University Irving Medical Center, who presented the results at TCT. "There is a great need to help improve outcomes for these very sick patients."

The MitraClip device is already approved in the U.S. for use in primary MR, a condition in which the mitral valve leaflets do not function properly due to a degenerative defect.

Whether the device is useful for secondary MR, in which the valve structure is normal, but the ventricle is enlarged, causing the valve leaflets to fail to prevent backward flow (known as mitral regurgitation), is unknown. In the procedure tested in COAPT for secondary MR, the MitraClip device is attached to the mitral valve leaflets via a catheter that is then removed, leaving the clipped valve in place with less regurgitation.

COAPT was a randomized, parallel-controlled, open-label multicenter trial evaluating transcatheter mitral valve repair with the MitraClip device in symptomatic heart failure patients with moderate-to-severe or severe secondary MR. A total of 614 subjects were randomized at 78 centers in the United States and Canada. A total of 302 patients were assigned to the device and guideline-directed medical therapy (GDMT) in the device group and 312 patients were assigned to GDMT alone in the control group.

The primary effectiveness endpoint was the annualized rate of all heart failure hospitalizations through 24 months and the primary safety endpoint was freedom from device-related complications at 12 months. After two years, there were 160 total heart failure hospitalizations among those who received the mitral clip versus 283 for the control group. The annualized rates of heart failure hospitalization were 35.8% per patient-year in the device group versus 67.9% per patient-year in the control group (HR 0.53, 95% CI [0.40 to 0.70]; p<0.001). In addition, the 12-month freedom from device-related complications was 96.6% [lower 95% confidence limit, 94.8%], which exceeded the performance goal of 88.0% for the primary safety endpoint (p<0.001). All-cause mortality at 24 months with the device was 29.1% compared to 46.1% in the control group (HR 0.62, 95% CI [0.46 to 0.82]; p<0.001).

In addition to the reductions in hospitalizations and mortality, device treatment also resulted in improvements in quality-of-life measures and functional capacity. The study found a mean 12.5-point increase in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score from baseline to 12 months after transcatheter mitral repair compared to a mean 3.6-point reduction in the control group. Similarly, exercise capacity as measured by six-minute walk distance (6MWD) decreased during 12-month follow-up by nearly 60 meters with GDMT alone but remained unchanged after transcatheter mitral repair. Heart failure classification (NYHA functional class) was also improved to a greater degree with the transcatheter device compared with GDMT alone at all follow-up times. Patients treated with the MitraClip also had a lower incidence of heart transplant or a left ventricular assist device (LVAD) (4.4% for the device group versus 9.5% for the control group).

"At two years, transcatheter mitral valve repair with the MitraClip device was found to be safe and effective. It substantially reduced the rate of hospitalizations and mortality, while improving quality-of-life and functional capacity," added Dr. Stone. "This procedure gives cardiologists an important option for high-risk heart failure patients with secondary MR who remain symptomatic despite optimal medical therapy."
-end-
The COAPT trial was funded by Abbott Vascular. Dr. Stone reported consulting fees from Neovasc, Valfix, and Gore, as well as equity/options in Ancora. He also reported that his employer, Columbia University, receives royalties from Abbott for sale of the MitraClip.

About CRF and TCT

The Cardiovascular Research Foundation (CRF) is a nonprofit research and educational organization dedicated to helping doctors improve survival and quality of life for people suffering from heart and vascular disease. For over 25 years, CRF has helped pioneer innovations in interventional cardiology and educated doctors on the latest treatments for heart disease.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of CRF and the world's premier educational meeting specializing in interventional cardiovascular medicine. Now in its 30th year, TCT features major medical research breakthroughs and gathers leading researchers and clinicians from around the world to present and discuss the latest evidence-based research in the field. TCT also includes interactive training where clinicians can gain vital skills to apply immediately to their practices.

For more information, visit http://www.crf.org and http://www.tctconference.com.

Cardiovascular Research Foundation

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.